Literature DB >> 16328004

RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.

Yohann Wittrant1, François Lamoureux, Kanji Mori, Anne Riet, Akira Kamijo, Dominique Heymann, Françoise Redini.   

Abstract

The POS-1 murine model of osteolytic osteosarcoma was used to elucidate the molecular and cellular mechanisms involved in the development of primary bone tumors and associated lung metastasis. The POS-1 cell line is derived from an osteosarcoma tumor which develops spontaneously in C3H mice. The POS-1 cell line was characterized in vitro by mineralization capacity and expression of bone markers by semi-quantitative RT-PCR, compared to primary osteoblasts and bone marrow cells. POS-1 cells showed no mineralization capacity and exhibited an undifferentiated phenotype, expressing both osteoblastic and unexpected osteoclastic markers (TRAP, cathepsin K and RANK). Thereby, experiments were performed to determine whether RANK was functional, by studying the biological activity of murine RANKL through the receptor RANK expressed on POS-1 cells. Results revealed a RANKL-induced increase in ERK phosphorylation, as well as BMP-2 induction at the mRNA and protein levels, and a decrease of POS-1 cell proliferation in the presence of 10 ng/ml RANKL. BMP-2 induction is dependent on the ERK 1/2 signal transduction pathway, as its expression is abolished in the presence of UO126, a specific synthetic inhibitor of the ERK 1/2 pathway. Moreover, a 2-fold molar excess of soluble RANK blocks the RANKL-induced BMP-2 expression, demonstrating that the biological effects of RANKL observed in POS-1 cells are mediated by RANK. This is the first report describing a functional RANK expressed on osteosarcoma cells, as shown by its ability to induce signal transduction pathways and biological activity when stimulated by RANKL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16328004

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  20 in total

1.  Skeletal imaging effects of pamidronate therapy in osteosarcoma patients.

Authors:  Anita P Price; Sara J Abramson; Sinchun Hwang; Alexander Chou; Roger Bartolotta; Paul Meyers; Douglas S Katz
Journal:  Pediatr Radiol       Date:  2010-10-30

2.  RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities.

Authors:  Xiaobin Cui; Hao Peng; Jing Jin; Tingting Li; Shumao Zhang; Tingting Jin; Su Li; Chunxia Liu; Weihua Liang; Feng Li; Yunzhao Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 3.  Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.

Authors:  Maria V Deligiorgi; Mihalis I Panayiotidis; John Griniatsos; Dimitrios T Trafalis
Journal:  Clin Exp Metastasis       Date:  2019-10-01       Impact factor: 5.150

Review 4.  Invasion and metastasis of renal cell carcinoma.

Authors:  Shuji Mikami; Mototsugu Oya; Ryuichi Mizuno; Takeo Kosaka; Ken-ichi Katsube; Yasunori Okada
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

5.  Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk.

Authors:  Kanji Mori; Frederic Blanchard; Celine Charrier; Severine Battaglia; Kosei Ando; Laurence Duplomb; Leonard D Shultz; Francoise Redini; Dominique Heymann
Journal:  Cancer Sci       Date:  2008-10-18       Impact factor: 6.716

Review 6.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

Review 7.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

8.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.

Authors:  François Lamoureux; Gaëlle Picarda; Julie Rousseau; Clothilde Gourden; Séverine Battaglia; Céline Charrier; Bruno Pitard; Dominique Heymann; Françoise Rédini
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

9.  Species-specific cis-regulatory elements in the 3'-untranslated region direct alternative polyadenylation of bone morphogenetic protein 2 mRNA.

Authors:  Donglin Liu; David T Fritz; Melissa B Rogers; Aaron J Shatkin
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

Review 10.  Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.

Authors:  Akio Sakamoto; Yukihide Iwamoto
Journal:  Rev Recent Clin Trials       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.